Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.4 USD | +3.34% | -10.05% | -61.32% |
Apr. 26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
Apr. 12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.32% | 354M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- RVNC Stock
- News Revance Therapeutics, Inc.
- Mizuho Adjusts Revance Therapeutics' Price Target to $16 From $35, Maintains Buy Rating